Program
IBI356
A development code. Also written as “IBI356 for MAD” and “IBI356 for SAD”.
Its studies are mostly in Dermatitis, Atopic, led by Innovent Biologics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 20 open or running | phase 2since Dec 15, 2025 | Dec 12, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06193434 · 99 enrolled · China
- Dec 15, 2025Phase 2 study in Dermatitis, AtopicPhase 2 reachedNCT07330934 · 18 enrolled · China
- Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT07330934 · “Sponsor Decision”
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07330934Dermatitis, Atopic · China | 2 | Terminated | Aug 18, 2026 | 18 |
| NCT06193434Healthy Participants · China | 1 | Completed | Aug 20, 2025 | 99 |
How it is read
Names in the registry
- “IBI356”, 1 entry
- “IBI356 for MAD”, 1 entry
- “IBI356 for SAD”, 1 entry
Codes read as this program: IBI356.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.